Stockscreener 앱 받기
8.33
0.72%
0.00
전일 마감가:
$8.33
열려 있는:
$8.38
하루 거래량:
37,432
Relative Volume:
0.25
시가총액:
$2.60B
수익:
$391.87M
순이익/손실:
$-441.45M
주가수익비율:
-4.5027
EPS:
-1.85
순현금흐름:
$-301.21M
1주 성능:
-2.44%
1개월 성능:
-27.48%
6개월 성능:
-32.34%
1년 성능:
-37.06%
1일 변동 폭
$8.29
$8.47
1주일 범위
$8.04
$8.64
52주 변동 폭
$7.35
$14.76
Alvotech Stock (ALVO) Company Profile
ALVO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALVO
Alvotech
|
8.37 | 2.60B | 391.87M | -441.45M | -301.21M | -1.85 |
|
ZTS
Zoetis Inc
|
149.41 | 66.56B | 9.26B | 2.49B | 2.30B | 5.47 |
|
HLN
Haleon Plc Adr
|
10.45 | 45.61B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.29 | 45.01B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
13.93 | 15.25B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
291.62 | 12.79B | 2.76B | 1.11B | 898.10M | 22.77 |
Alvotech Stock (ALVO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-14 | 개시 | UBS | Buy |
| 2024-01-29 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2023-10-20 | 업그레이드 | Citigroup | Sell → Neutral |
| 2023-09-21 | 개시 | Barclays | Equal Weight |
| 2022-09-07 | 개시 | Morgan Stanley | Equal-Weight |
| 2022-09-06 | 다운그레이드 | Citigroup | Buy → Sell |
| 2022-07-26 | 개시 | Citigroup | Buy |
모두보기
Alvotech 주식(ALVO)의 최신 뉴스
Xbrane Approves Deal Giving Away Cimzia Rival To Alvotech - insights.citeline.com
Legal & General Group Plc Trims Holdings in Alvotech (NASDAQ:ALVO) - MarketBeat
FY2025 EPS Estimates for Alvotech Cut by Northland Capmk - MarketBeat
Alvotech (NASDAQ:ALVO) Sets New 52-Week LowHere's Why - MarketBeat
Alvotech (NASDAQ:ALVO) Stock Price Down 6.9%What's Next? - MarketBeat
Announcement from extra general meeting in Xbrane Biopharma AB - TradingView
Benign Growth For Alvotech (NASDAQ:ALVO) Underpins Stock's 25% Plummet - simplywall.st
Alvotech (NASDAQ:ALVO) Trading Down 3.5%Should You Sell? - MarketBeat
Major Drug Launch: Teva's New Stelara Biosimilar Targets Multiple Billion-Dollar Markets - Stock Titan
Alvotech (NASDAQ:ALVO) Sets New 12-Month LowShould You Sell? - MarketBeat
Alvotech stock hits 52-week low at $8.88 amid market challenges - Investing.com Canada
Alvotech stock hits 52-week low at $8.88 amid market challenges By Investing.com - Investing.com South Africa
The Escalator: HHS, Spectrum Science, Alvotech and more - Medical Marketing and Media
Oaktree Capital Management LP Lowers Holdings in Alvotech (NASDAQ:ALVO) - MarketBeat
Who’s Hired? Alvotech Appoints Strategy And Quality Chiefs - insights.citeline.com
Biosimilars Help Alvotech Revenues Soar Over 400% Year Over Year - Center for Biosimilars®
Alvotech (NASDAQ:ALVO) Trading Down 7.6%Should You Sell? - MarketBeat
Alvotech (NASDAQ:ALVO) Posts Earnings Results, Beats Expectations By $0.50 EPS - MarketBeat
Alvotech (NASDAQ:ALVO) Just Reported And Analysts Have Been Lifting Their Price Targets - Yahoo Finance
Earnings call transcript: Alvotech’s Q4 2024 results show revenue surge By Investing.com - Investing.com Australia
Aurion names Arnaud Lacoste CEO - BioCentury
Alvotech Reveals Ramp-Up In Development As Sales Explode In 2024 - insights.citeline.com
Alvotech Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags - simplywall.st
ALVO Latest Report - AInvest
Alvotech Achieves Record Revenue Growth in 2024 - TipRanks
Earnings call transcript: Alvotech’s Q4 2024 results show revenue surge - Investing.com India
Trump Must Be ‘Harsh’ With Big Pharma, Says Icelandic Drugmaker - Bloomberg.com
Alvotech Appoints Dr. Balaji V. Prasad As Chief Strategy Officer - MarketScreener
Alvotech Appoints New Chief Strategy Officer to Strengthen Market Position - TipRanks
Alvotech Achieves Record 2024 Financial Results and Expands Biosimilar Pipeline - TipRanks
Iceland's Alvotech Appoints Chief Strategy Officer - MarketScreener
Alvotech Appoints Dr. Balaji V. Prasad as Chief Strategy Officer - The Manila Times
Alvotech earnings missed by $0.04, revenue topped estimates - Investing.com Australia
Alvotech SA reports results for the quarter ended December 31Earnings Summary - TradingView
Alvotech earnings missed by $0.04, revenue topped estimates By Investing.com - Investing.com South Africa
Alvotech : Press Release Full Year 2024 - MarketScreener
Alvotech Reports Record Results for 2024 and Provides Business Update - The Manila Times
Deal Watch: Eyenovia Looks At New Direction In Proposed Merger With Betaliq - insights.citeline.com
Alvotech And Advanz Make First Omalizumab Filing - Citeline News & Insights
Alvotech (ALVO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.71%
자본화:
|
볼륨(24시간):